Rachel Fong
Rachel Fong
Director, Sales and Alliances
Integral Molecular
Rob Roovers
Rob Roovers, PhD
Senior Director, Preclinical Development
LAVA Therapeutics
Pavel Nikitin
Pavel Nikitin, PhD
Senior Director, Antibody Engineering
Immunome

Rigorous specificity analysis is critical for successful drug development and a safety requirement for monoclonal antibody (mAb) based therapies, such as CAR-T, entering IND. Tissue cross-reactivity (TCR) studies have been traditionally used to screen for off-target binding, however, with poor predictive value for in vivo safety and toxicity. Integral Molecular has developed the Membrane Proteome Array (MPA) platform to de-risk mAb-based therapeutics by testing specificity across the full human membrane proteome expressed in live cells. Using sensitive high-throughput flow cytometry to identify binding interactions on a protein level, this technology has emerged as the leading solution for antibody specificity profiling.

In this GEN webinar, our panelists will discuss their experiences using the MPA to rapidly identify potential off-target interactions for IND filings. We will also describe the newest additions to this 6,000-protein cell array and the adoption of MPA technology for regulatory filings for CAR-T and antibody therapies where conventional approaches do not suffice.

A live Q&A session will follow the presentation, offering you a chance to pose questions to our expert panelists.


Produced with support from:

Integral Molecular logo